Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

On Mar 13, 2013, we retained The Cooper Companies Inc. (COO - Analyst Report) at Neutral after the company beat Zacks Consensus Estimates for earnings and revenue for fiscal first quarter 2013.

Why the Retention?

Cooper released its results for the fiscal first quarter on Mar 7. The company posted adjusted earnings per share of $1.23 per share, higher than the Zacks Consensus Estimate of earnings of $1.20 a share. Revenues in the reported quarter surged 16% (up 11% in constant currency, barring acquisitions) year over year to $379.8 million, beating the Zacks Consensus Estimate of $365 million.

Over the past 30 days, the Zacks Consensus Estimate for fiscal 2013 has moved up by 2 cents to $6.04. For fiscal 2014, the Zacks Consensus Estimate has increased by 5 cents to $6.70 during the same timeframe.

For fiscal 2013, Cooper envisages revenues in the range of $1,575 million and $1,625 million (earlier $1,565 million to $1,625 million), comprising CVI sales of $1,260 million to $1,290 million and CSI sales of $315 million to $335 million.

Cooper expects reported earnings per share in the band of $6.22 and $6.37 (earlier $5.90 and $6.10) for fiscal 2013. COO also guided to adjusted earnings per share between $5.95 and $6.10 (earlier $5.90 and $6.10). Free cash flow is expected in the range of $170 million to $200 million (earlier $210 million to $230 million).

The stock carries a short-term Zacks Rank #2 (Buy). We are positive on Cooper as it reported a good performance in the reported quarter. Moreover, this contact lens and womens’ health focused company continues to expand margins, synergize acquisitions and expand geographical reach. However, COO faces formidable competition in each of its major product lines.

Other Stocks to Consider

We are positive about Medical Action Industries Inc. , which carries a Zacks Rank #1 (Strong Buy). We are also positive about Steris Corp. (STE - Snapshot Report) and Becton, Dickinson and Company (BDX - Analyst Report) each of which carry a Zacks Rank #2 (Buy) and are expected to do well.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%